Casi Pharmaceuticals (CASI) announced the appointment of David Cory as CEO and a member of the board of directors. Wei-Wu He will step down as the CEO and will remain as executive chairman of the board of directors. Most recently, Cory was CEO and director of LIB Therapeutics which completed Phase 3 registration-enabling trials for its lead cardiovascular disease program and filed for regulatory approval.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks